AbFero Pharmaceuticals
David Ashford Jones is Director of Parkinson’s Research for AbFero, Ltd., a UK subsidiary of AbFero Pharmaceuticals, Inc. Mr. Ashford Jones heads a pharmaceutical and healthcare consulting firm, Sagio, which he founded in 2009 after 20 years as a sales and marketing executive for leading pharmaceutical companies, including Schering Plough, AstraZeneca, Schering Healthcare, and Parke Davis. Since being diagnosed with Parkinson’s Disease (PD) in 2010, he has become an active PD patient advocate, advising and volunteering his time to numerous organizations including The Cure Parkinson’s Trust, where he is currently a trustee. Mr. Ashford Jones received a BSc Hons in Physiology & Pharmacology from the University of Sheffield and earned an MBA at the University of Warwick.
This person is not in any offices
AbFero Pharmaceuticals
AbFero Pharmaceuticals is a privately held clinical-stage pharmaceutical company dedicated to treating diseases of iron overload. Their therapeutic platform addresses transfusion-related iron overload (TIO) and iron accumulation associated with diseases of aging, such as age-related macular degeneration (AMD), and Parkinson’s disease.